Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma: Appraisal consultation document

Due to uncertain cost-effectiveness estimates, DRAFT guidance does not recommend polatuzumab with rituximab and bendamustine as an option for treating relapsed/refractory diffuse large B-cell lymphoma in adults who cannot have a haematopoietic stem cell transplant.

National Institute for Health and Care Excellence